153 related articles for article (PubMed ID: 38632477)
1. Prognostic implication of 1-year decline in diffusing capacity in newly diagnosed idiopathic pulmonary fibrosis.
Lee H; Kim SY; Park YS; Choi SM; Lee JH; Park J
Sci Rep; 2024 Apr; 14(1):8857. PubMed ID: 38632477
[TBL] [Abstract][Full Text] [Related]
2. Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.
Toi Y; Takei R; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Fukuoka J; Johkoh T; Kondoh Y
Respir Investig; 2021 May; 59(3):335-341. PubMed ID: 33551330
[TBL] [Abstract][Full Text] [Related]
3. Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis.
Yoon HY; Kim TH; Seo JB; Lee SM; Lim S; Lee HN; Kim N; Han M; Kim DS; Song JW
Respirology; 2019 Jan; 24(1):55-62. PubMed ID: 30136753
[TBL] [Abstract][Full Text] [Related]
4. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
[TBL] [Abstract][Full Text] [Related]
5. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
6. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
[TBL] [Abstract][Full Text] [Related]
7. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
Doubková M; Švancara J; Svoboda M; Šterclová M; Bartoš V; Plačková M; Lacina L; Žurková M; Binková I; Bittenglová R; Lošťáková V; Merta Z; Šišková L; Tyl R; Lisá P; Šuldová H; Petřík F; Pšikalová J; Řihák V; Snížek T; Reiterer P; Homolka J; Musilová P; Lněnička J; Palúch P; Hrdina R; Králová R; Hortvíková H; Strenková J; Vašáková M
Clin Respir J; 2018 Apr; 12(4):1526-1535. PubMed ID: 28862397
[TBL] [Abstract][Full Text] [Related]
8. Influence of radiological emphysema on lung function test in idiopathic pulmonary fibrosis.
Bodlet A; Maury G; Jamart J; Dahlqvist C
Respir Med; 2013 Nov; 107(11):1781-8. PubMed ID: 24051272
[TBL] [Abstract][Full Text] [Related]
9. Respiratory Impedance is Associated with Ventilation and Diffusing Capacity in Patients with Idiopathic Pulmonary Fibrosis Combined with Emphysema.
Yamamoto Y; Hirata H; Shiroyama T; Kuge T; Matsumoto K; Yoneda M; Yamamoto M; Naito Y; Suga Y; Fukushima K; Miyake K; Koyama S; Iwahori K; Nagatomo I; Takeda Y; Kumanogoh A
Int J Chron Obstruct Pulmon Dis; 2022; 17():1495-1506. PubMed ID: 35801120
[TBL] [Abstract][Full Text] [Related]
10. Lung function outcomes in the INPULSIS
Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
[TBL] [Abstract][Full Text] [Related]
11. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis.
Jacob J; Bartholmai BJ; Rajagopalan S; Kokosi M; Maher TM; Nair A; Karwoski R; Renzoni E; Walsh SLF; Hansell DM; Wells AU
Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28679612
[TBL] [Abstract][Full Text] [Related]
12. Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome.
Okuda R; Hagiwara E; Katano T; Ikeda S; Sekine A; Kitamura H; Baba T; Okudela K; Ohashi K; Ogura T
Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(1):39-46. PubMed ID: 32476935
[TBL] [Abstract][Full Text] [Related]
13. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
[TBL] [Abstract][Full Text] [Related]
14. Mortality surrogates in combined pulmonary fibrosis and emphysema.
Zhao A; Gudmundsson E; Mogulkoc N; van Moorsel C; Corte TJ; Vasudev P; Romei C; Chapman R; Wallis TJM; Denneny E; Goos T; Savas R; Ahmed A; Brereton CJ; van Es HW; Jo H; De Liperi A; Duncan M; Pontoppidan K; De Sadeleer LJ; van Beek F; Barnett J; Cross G; Procter A; Veltkamp M; Hopkins P; Moodley Y; Taliani A; Taylor M; Verleden S; Tavanti L; Vermant M; Nair A; Stewart I; Janes SM; Young AL; Barber D; Alexander DC; Porter JC; Wells AU; Jones MG; Wuyts WA; Jacob J
Eur Respir J; 2024 Apr; 63(4):. PubMed ID: 37973176
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
[TBL] [Abstract][Full Text] [Related]
16. Lung function trajectories in patients with idiopathic pulmonary fibrosis.
Neely ML; Hellkamp AS; Bender S; Todd JL; Liesching T; Luckhardt TR; Oldham JM; Raj R; White ES; Palmer SM
Respir Res; 2023 Aug; 24(1):209. PubMed ID: 37612608
[TBL] [Abstract][Full Text] [Related]
17. Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume.
Du K; Zhu Y; Mao R; Qu Y; Cui B; Ma Y; Zhang X; Chen Z
Respir Res; 2022 Dec; 23(1):372. PubMed ID: 36550474
[TBL] [Abstract][Full Text] [Related]
18. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
19. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
[TBL] [Abstract][Full Text] [Related]
20. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis.
Akagi T; Matsumoto T; Harada T; Tanaka M; Kuraki T; Fujita M; Watanabe K
Respir Med; 2009 Aug; 103(8):1209-15. PubMed ID: 19251407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
